# Sequel Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sequel-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.sequelpharma.com
- Total disclosed funding: $20M
- Latest round: Series B (Aug 16, 2009)
- Investors on record: 5

## About

Sequel Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the acquisition, development, and marketing of targeted pharmaceutical products aimed at addressing specific therapeutic needs for improved patient outcomes.Sequel Pharmaceuticals is focused on developing specialty pharmaceuticals that cater to distinct therapeutic areas. Founded in 2007 and headquartered in San Diego, California, the company has made four deals, with its most recent funding round, a Venture Debt of USD 1.00 mn, secured on December 22, 2010, totaling USD 20.00 mn raised. The company does not have any known subsidiaries or parent organizations.Sequel Pharmaceuticals specializes in the acquisition, development, and marketing of specialty pharmaceutical products that target specific therapeutic areas. Their offerings include pharmaceutical solutions designed to address unmet medical needs, enhancing patient outcomes. The company markets its products primarily to healthcare providers, hospitals, and pharmacies, operating within the specialty pharmaceutical sector, and serving a diverse range of clients across the United States and select international markets.Sequel Pharmaceuticals generates revenue through the marketing of its specialty pharmaceutical products via direct sales to healthcare providers and partnerships with distributors. Their business involves B2B transactions predominantly with hospitals and pharmacies. The firm typically employs pricing structures aligned with market standards for specialty pharmaceuticals, which may involve volume-based pricing and tiered discounts for larger orders. Their flagship products contribute significantly to their revenue stream by ensuring a consistent supply to healthcare providers, fostering long-term relationships within the healthcare ecosystem.Sequel Pharmaceuticals intends to leverage recent funding to support the development of new pharmaceutical products and facilitate entry into new market regions. The additional resources from the USD 1.00 mn funding will aid in enhancing their product line and expanding their presence in targeted markets. As of December 2010, the company is strategizing to introduce innovative therapies aimed at specific health conditions, though no specific launch dates have been disclosed.

## Funding rounds

- Series B, Aug 16, 2009 — Domain Associates, Forward Ventures, InterWest Partners, Skyline Ventures, Montreux Equity Partners
- Series A, Sep 24, 2007, $20M — Domain Associates, Forward Ventures, InterWest Partners, Skyline Ventures, Montreux Equity Partners

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series B
- Forward Ventures (https://capitalatlas.ai/funds/forward-ventures) — Series A, Series B
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A, Series B
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series A, Series B
- Montreux Equity Partners (https://capitalatlas.ai/funds/montreux-equity-partners) — Series A, Series B